Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 17/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 11/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 11/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.60 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.60 |
| ▸ | CYP3A7 | P24462 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | CYP3A43 | Q9HB55 | 1/20 | 0.60 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.56 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.53 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.53 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.53 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.53 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.53 |
| ▸ | CYP51A1 | Q16850 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.52 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14581431 | 0.89 | CYP3A4 (0.49) | CYP3A4CYP2C9CYP2C19LMNACYP2B6 | |
| SCHEMBL7259777 | 0.89 | CYP3A4 (0.62) | CYP3A4CYP2C9CYP2C19LMNACYP2B6 | |
| SCHEMBL7268075 | 0.88 | CYP3A4 (0.70) | CYP3A4CYP2C9CYP2C19LMNACYP2B6 | |
| SCHEMBL7278330 | 0.88 | CYP3A4 (0.70) | CYP3A4CYP2C9CYP2C19LMNACYP2B6 | |
| SCHEMBL9826014 | 0.87 | CYP3A4 (0.72) | CYP3A4CYP2C9CYP2C19LMNACYP2B6 | |
| SCHEMBL7680346 | 0.84 | CYP3A4 (0.56) | CYP3A4CYP2C9CYP2C19LMNACYP2B6 | |
| SCHEMBL7680351 | 0.84 | CYP3A4 (0.56) | CYP3A4CYP2C9CYP2C19LMNACYP2B6 | |
| SCHEMBL9826002 | 0.84 | CYP3A4 (0.67) | CYP3A4CYP2C9CYP2C19LMNACYP2B6 | |
| SCHEMBL7682304 | 0.84 | CYP3A4 (0.67) | CYP3A4CYP2C9CYP2C19LMNACYP2B6 | |
| SCHEMBL9826570 | 0.83 | CYP3A4 (0.70) | CYP3A4CYP2C9CYP2C19LMNACYP2B6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0835252-B1 | TRIAZOLE ANTIFUNGAL AGENTS | PFIZER RES & DEV (IE) | 2003-07-30 | — | — | EP | claimed |
| WO-1997001552-A1 | TRIAZOLE ANTIFUNGAL AGENTS | PFIZER RESEARCH AND DEVELOPMENT COMPANY, N.V./S.A. (IE) | 1997-01-16 | — | — | WO | claimed |
| US-20070027115-A1 | Triazole derivatives useful in therapy | PFIZER INC. | 2007-02-01 | — | — | US | disclosed |
| US-20070027115-A1 | Triazole derivatives useful in therapy | PFIZER INC. | 2007-02-01 | — | — | US | disclosed |
| US-6977302-B2 | Triazole derivatives useful in therapy | AGOURON PHARMACEUTICALS, INC. (US) | 2005-12-20 | — | — | US | disclosed |
| US-20050130940-A1 | Triazole derivatives useful in therapy | PFIZER INC. | 2005-06-16 | — | — | US | disclosed |
| US-6790957-B2 | CONVERTING TERTIARY HYDROXY GROUP OF A TRIAZOLE ANTIFUNGAL COMPOUND INTO A PHOSPHATE GROUP TO IMPROVE AQUEOUS SOLUBILITY | PFIZER, INC. | 2004-09-14 | — | — | US | disclosed |
| US-20030144250-A1 | Triazole derivatives useful in therapy | GREEN STUART (GB) | 2003-07-31 | — | — | US | disclosed |
| EP-0835252-B1 | TRIAZOLE ANTIFUNGAL AGENTS | PFIZER RES & DEV (IE) | 2003-07-30 | — | — | EP | disclosed |
| US-6015825-A | Triazole antifungal agents | PFIZER INC. (US) | 2000-01-18 | — | — | US | disclosed |
| EP-0835252-A1 | TRIAZOLE ANTIFUNGAL AGENTS | Pfizer Research and Development Company, N.V./S.A. (IE) | 1998-04-15 | — | — | EP | disclosed |
| WO-1997001552-A1 | TRIAZOLE ANTIFUNGAL AGENTS | PFIZER RESEARCH AND DEVELOPMENT COMPANY, N.V./S.A. (IE) | 1997-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130940-A1 | Triazole derivatives useful in therapy | ERG28, CYP51A1, THOP1 | CYP3A4 61/4885CYP2C9 299/4885CYP2C19 138/4885 |
| US-20070027115-A1 | Triazole derivatives useful in therapy | ERG28, CYP51A1, THOP1 | CYP3A4 61/4885CYP2C9 299/4885CYP2C19 138/4885 |
| US-20030144250-A1 | Triazole derivatives useful in therapy | CYP51A1, THOP1, ERG28 | CYP3A4 87/4885CYP2C9 301/4885CYP2C19 202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.